Levi & Korsinsky, LLP alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action has been filed on behalf of shareholders who purchased securities between February 28, 2024 and February 25, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

PRCT shares declined more than 75%, from approximately $100.00 during the Class Period to less than $25.00 after the Class Period, an alleged loss of more than $75.00 per share. To be considered for lead plaintiff, investors must file by September 22, 2026.

CEO, CFO Securities Liability Section 20(a) Control Person Claims

The complaint names Reza Zadno, former Chief Executive Officer and director, and Kevin Waters, Chief Financial Officer, among the individual defendants. The pleading asserts that senior officers controlled or influenced PROCEPT BioRobotics’ public statements about handpiece utilization, procedure demand, customer ordering behavior, and the relationship between handpiece sales and actual procedures.

The action claims investors relied on those public representations while the Company’s recurring revenue model depended heavily on disposable handpiece sales tied to its AquaBeam Robotic Systems.

Alleged Control Person Liability

  • The complaint alleges that senior executives had authority over SEC filings, earnings releases, investor calls, and operational metrics.

  • Plaintiffs contend that public statements emphasized utilization growth while allegedly omitting discount-driven bulk ordering.

  • The action asserts that handpiece sales allegedly exceeded actual procedure levels during the Class Period.

  • The complaint charges that excess field inventory ultimately grew to more than 10,000 units.

  • Plaintiffs allege that insiders sold approximately $90 million in PROCEPT BioRobotics shares during the Class Period.

Sarbanes-Oxley Certification Obligations

The complaint further alleges that executive certifications under Sarbanes-Oxley Sections 302 and 906 are relevant because investors were asked to trust the accuracy and completeness of corporate disclosures. As averred, the alleged omission of the discount program and inventory overstocking risks made those disclosures materially misleading.

“Corporate officers have a duty to ensure their companies’ public statements are accurate and complete. Here, the complaint alleges that investors were not told key facts about handpiece demand and inventory while PRCT shares later lost more than 75% of their value.” — Joseph E. Levi, Esq.

Submit your information here or call (212) 363-7500.

Levi & Korsinsky, LLP is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the PRCT Lawsuit

Q: What specific misstatements does the PRCT lawsuit allege? A: The complaint alleges PROCEPT BioRobotics Corporation made materially false or misleading statements regarding handpiece utilization, the relationship between handpiece sales and actual procedures, customer ordering behavior, and the alleged impact of an undisclosed discount program during the Class Period. When procedure data, excess inventory, and the alleged discount-driven ordering issues were disclosed, the stock price declined sharply.

Q: What court was the PRCT class action filed in? A: The case was filed in the United States District Court for the Northern District of California, governed by the Private Securities Litigation Reform Act of 1995.

Q: Who are the defendants named in the PRCT lawsuit? A: The complaint names PROCEPT BioRobotics Corporation and individual defendants including senior executives who allegedly signed SEC filings, made public statements, or certified financial disclosures under Sarbanes-Oxley.

Q: How much did PRCT stock drop? A: Shares fell approximately 75%, a decline of more than $75.00 per share, after the Company disclosed actual procedure data, cumulative excess field inventory of more than 10,000 units, and the alleged effects of a previously undisclosed discount program.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my PRCT shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to contact the firm. Securities class actions are generally handled on a pure contingency basis. No upfront fees, no retainer, and no out-of-pocket costs. Any attorneys’ fees and expenses awarded to class counsel are subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.

Media gallery

About The Author
Business Wire